Tom van Meerten
dr.
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting
Published in: Annals of Oncology
Access to document
10.1093/annonc/mdy482
document
H. T. van der Galien, M. Hoogendoorn, R. E. Kibbelaar, T. van Meerten, R. S. van Rijn
Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?
Published in: Molecular and Cellular Oncology
Access to document
10.1080/23723556.2019.1600349
document
Innate immune checkpoint CD47 has emerged as a prominent target for cancer immunotherapy and defining biomarkers predictive of response will be a crucial step towards clinical implementation. Hereto, we investigated the importance of a previously reported requisite for SLAM family member 7(SLAMF7) expression on cancer cell phagocytosis for effective CD47 antibody therapy.
Renee Bouwstra, Tom van Meerten, Edwin Bremer
Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis
Published in: Critical Reviews in Oncology/Hematology
Access to document
10.1016/j.critrevonc.2018.09.007
document
Introduction and aim: Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after solid organ and hematopoietic stem cell transplantation, associated with significant morbidity and mortality. In this systematic review we evaluated the clinical performance of advanced imaging modalities at diagnosis and treatment response evaluation of PTLD patients after solid organ and hematopoietic stem cell transplantation. Methods: We have carried out a literature search until December 15, 2017 using PubMed/Medline, Embase, “Web of Science” and Cochrane Library databases concerning the performance of computed tomography (CT), magnetic resonance imaging (MRI)...
F M Montes de Jesus, T C Kwee, M Nijland, X U Kahle, G Huls, R A J O Dierckx, T van Meerten, O Gheysens, D Dierickx, V Vergote, W Noordzij, A W J M Glaudemans
CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)
Tom Van Meerten, Renee Bouwstra, Yuan He, de Boer Janneke, Hilde Kooistra, Rudolf Fehrmann, Emanuele Ammatuna, Gerwin Huls, Edwin Bremer
Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
Published in: Cancers
Access to document
10.3390/cancers10110459
document
Current genomic models in diffuse large B-cell lymphoma (DLBCL) are based on single tumor biopsies, which might underestimate heterogeneity. Data on mutational evolution largely remains unknown. An exploratory study using whole exome sequencing on paired (primary and relapse) formalin fixed paraffin embedded DLBCL biopsies (n = 14) of 6 patients was performed to globally assess the mutational evolution and to identify gene mutations specific for relapse samples from patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. A minority of the mutations detected in the primary sample (median...
Marcel Nijland, Annika Seitz, Martijn Terpstra, Gustaaf W van Imhoff, Philip M Kluin, Tom van Meerten, Çiğdem Atayar, Léon C van Kempen, Arjan Diepstra, Klaas Kok, Anke van den Berg